Literature DB >> 34473337

Analysis of Cytotoxic Effects of Zerumbone in Malignant Glioblastoma Cells.

Mohammad Jalili-Nik1, Amir R Afshari2, Khadijeh Mahboobnia3, Paul C Guest4, Tannaz Jamialahmadi5,6, Amirhossein Sahebkar7,8,9.   

Abstract

Glioblastoma multiforme (GBM) is an aggressive tumor in the central nervous system with a poor prognosis. Currently, the main interventions include surgery, chemotherapy, and radiotherapy. Recently, several natural products have been reported as potentially effective and safer treatment options. Here, we studied the effects of zerumbone, a sesquiterpene compound derived from Zingiber zerumbet Smith rhizomes, on human GBM U-87 MG cells in vitro. To meet this purpose, we used a cytotoxicity assay, as well as a quantitative polymerase chain reaction of apoptosis-related genes and western blot analysis of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a transcription factor that controls the production of cytokines and molecules involved in cell survival.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cytotoxicity; Glioblastoma multiforme; Natural products; Western blot; Zerumbone; qPCR

Mesh:

Substances:

Year:  2022        PMID: 34473337     DOI: 10.1007/978-1-0716-1558-4_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment

Authors:  Farina Hanif; Kanza Muzaffar; Kahkashan Perveen; Saima M Malhi; Shabana U Simjee
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01

2.  Auraptene-induced cytotoxicity mechanisms in human malignant glioblastoma (U87) cells: role of reactive oxygen species (ROS).

Authors:  Amir R Afshari; Mohammad Jalili-Nik; Mohammad Soukhtanloo; Ahmad Ghorbani; Hamid R Sadeghnia; Hamid Mollazadeh; Mostafa Karimi Roshan; Farzad Rahmani; Hamed Sabri; Mohammad Mahdi Vahedi; Seyed Hadi Mousavi
Journal:  EXCLI J       Date:  2019-07-30       Impact factor: 4.068

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.